Soluble fms-like tyrosine kinase-1 (sFlt-1 or sVEGFR-1) is a tyrosine kinase protein with antiangiogenic properties. A non-membrane associated splice variant of VEGF receptor 1 (Flt-1), sFlt-1 binds the angiogenic factors VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), reducing blood vessel growth through reduction ...

Jan 7, 2016 · The ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) to placental growth factor (PlGF) is elevated in pregnant women before the clinical onset of preeclampsia, but its predictive value in...

May 20, 2019 · sFlt⁃1也称为可溶性血管内皮生长因子受体，是血管内皮生长因子受体（vascular endothelial growth factor receptor，VEGFR）1 的分泌性剪接变体，只有配体结合域，缺少胞质区和跨膜区。

Dec 28, 2018 · 2018 年最新的一项研究提示：sFlt-1/PlGF 可做为诊断和预测 PE 的一项有效参数。sFlt-1/PlGF 的增加与临床需要分娩密切相关。sFlt-1/PlGF 适用于高风险子痫前期患者的密切监测，帮助临床决策。 [5]

sFlt-1是血管内皮生长因子受体1（Vascular endothelial growth factor receptor 1，VEGFR-1）的异构体，最初是在人类脐静脉内皮细胞上被发现，在绒毛和绒毛外滋养细胞上浓度较高，但只有配体结合域缺少胞质区和跨膜区。

The anti-angiogenic factor, soluble fms-like tyrosine kinase 1 (sFlt-1) and the pro-angiogenic factor, placental growth factor (PlGF), can be measured in plasma and serum and are usually reported as a ratio, which specifically relates to the onset and severity of preeclampsia.

Jun 16, 2022 · 受损的胎盘产生更高浓度的可溶性fms样酪氨酸激酶-1 (sFlt-1)，这是一种血管内皮生长因子(VEGF)和胎盘生长因子(PlGF)的可溶性受体，释放到母体循环中并参与内皮功能障碍。

Pre-eclampsia (PE) is characterized by placental and maternal endothelial dysfunction, and associated with fetal growth restriction (FGR), placental abruption, preterm delivery and stillbirth. The angiogenic factors soluble fms-like tyrosine kinase …

Jul 27, 2020 · Preeclampsia is characterized by angiogenic imbalance (AI), sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) is useful for its diagnosis and prediction of adverse outcomes...

可溶性类fms酪氨酸激酶－1( sFlt－1) 是一种具有酪氨酸激酶活性的糖蛋白，属于Ⅲ型受体酪氨酸激酶家族，是血管内皮生长因子 ( VEGF) 和胎盘生长因子( PLGF) 强有力的抑制物，可与VEGF和PLGF结合使其丧失活性，sFlt－1具有阻挠血管生长的作用，有研究表明sFlt－1可能 ...